Bioventus Inc. (BVS)
Bioventus Inc. (BVS)
| Cash Flow | 2026-03-28 | 2025-12-31 | 2025-09-27 | 2025-06-28 |
|---|---|---|---|---|
| Income (loss) from continuing operations | NaN | 27,274 | NaN | NaN |
| Net income (loss) | -6,010 | NaN | 4,006 | 5,950 |
| Depreciation and amortization | 11,205 | 11,694 | 11,403 | 23,914 |
| Provision for credit losses | 230 | 312 | 101 | 843 |
| Equity-based compensation | 3,264 | 3,440 | 3,176 | 6,057 |
| Deferred income taxes | 135 | -1,131 | 135 | 87 |
| Change in fair value of contingent consideration | NaN | 0 | 0 | 0 |
| Impairments of assets | NaN | 0 | 0 | 0 |
| Loss on extinguishment | NaN | 0 | -326 | NaN |
| Loss on disposals | 0 | 0 | 1 | -82 |
| Unrealized loss (gain) on foreign currency fluctuations | -54 | 27 | -32 | 365 |
| Other, net | 275 | 155 | 243 | 763 |
| Accounts receivable | -7,318 | -1,885 | -1,824 | 4,625 |
| Inventories | 2,648 | -12,968 | -291 | 4,690 |
| Accounts payable and accrued expenses | -15,367 | -4,444 | 7,311 | -22,681 |
| Other current and noncurrent assets and liabilities | -522 | 4,202 | -1,251 | -1,272 |
| Net cash from operating activities - continuing operations | NaN | 74,673 | NaN | NaN |
| Net cash from operating activities - discontinued operations | NaN | 0 | NaN | NaN |
| Net cash from operating activities | 8,934 | 37,968 | 30,098 | 6,607 |
| Settlement from the sale of a business | NaN | NaN | 0 | 686 |
| (settlement) proceeds from the sale of a business | NaN | -686 | NaN | NaN |
| Purchase of property and equipment | 574 | 580 | 473 | 1,509 |
| Investments and acquisition of distribution rights | NaN | 0 | 0 | 0 |
| Net cash from investing activities - continuing operations | NaN | -3,248 | NaN | NaN |
| Net cash from investing activities - discontinued operations | NaN | 0 | NaN | NaN |
| Net cash from investing activities | -574 | -580 | -473 | -2,195 |
| Proceeds from issuance of class a common stock | 120 | 511 | 96 | 1,467 |
| Tax withholdings on equity-based compensation | 1,044 | 0 | 9 | NaN |
| Receipt of deferred consideration | NaN | 0 | NaN | NaN |
| Payment of contingent consideration | 0 | 0 | 0 | 19,771 |
| Borrowing on revolver | 0 | 0 | 30,000 | 15,000 |
| Payment on revolver | 0 | 25,000 | 10,000 | 10,000 |
| Proceeds from the issuance of long-term debt, net of discount | NaN | 0 | 31,907 | NaN |
| Payments on the extinguishment of long-term debt | NaN | 0 | 65,765 | NaN |
| Debt refinancing costs | NaN | NaN | 697 | 0 |
| Debt financing costs | NaN | 697 | NaN | NaN |
| Payments on long-term debt | 22,000 | 3,750 | 5,302 | 0 |
| Other, net | -220 | -208 | -207 | -412 |
| Net cash from financing activities | -23,144 | -28,447 | -19,977 | -13,716 |
| Effect of exchange rate changes on cash | -608 | 133 | -394 | 632 |
| Net change in cash and cash equivalents | -15,392 | 9,074 | 9,254 | -8,672 |
| Cash and cash equivalents at the beginning of the period | 51,238 | 42,164 | 41,582 | NaN |
| Cash and cash equivalents at the end of the period | 35,846 | 51,238 | 42,164 | NaN |